Tredje AP fonden Purchases 31,861 Shares of Stryker Corporation $SYK

Tredje AP fonden lifted its position in Stryker Corporation (NYSE:SYK) by 32.0% during the 4th quarter, HoldingsChannel reports. The firm owned 131,561 shares of the medical technology company’s stock after acquiring an additional 31,861 shares during the quarter. Tredje AP fonden’s holdings in Stryker were worth $46,240,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Czech National Bank increased its stake in Stryker by 3.9% during the fourth quarter. Czech National Bank now owns 90,755 shares of the medical technology company’s stock worth $31,898,000 after acquiring an additional 3,366 shares during the last quarter. Davis R M Inc. increased its stake in Stryker by 1.8% during the third quarter. Davis R M Inc. now owns 138,732 shares of the medical technology company’s stock worth $51,285,000 after acquiring an additional 2,512 shares during the last quarter. Terra Alpha Investments LLC bought a new stake in Stryker during the third quarter worth approximately $1,216,000. Kepler Cheuvreux Suisse SA bought a new stake in Stryker during the third quarter worth approximately $27,952,000. Finally, Daymark Wealth Partners LLC increased its stake in Stryker by 436.0% during the fourth quarter. Daymark Wealth Partners LLC now owns 45,863 shares of the medical technology company’s stock worth $16,119,000 after acquiring an additional 37,307 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Trading Up 2.0%

SYK opened at $312.99 on Tuesday. The stock has a market cap of $119.99 billion, a price-to-earnings ratio of 36.23, a P/E/G ratio of 1.93 and a beta of 0.80. The stock’s 50 day moving average price is $328.54 and its 200-day moving average price is $351.06. Stryker Corporation has a one year low of $281.00 and a one year high of $404.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK) last released its earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The business had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. The company’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Tuesday, June 30th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.1%. Stryker’s dividend payout ratio is currently 40.74%.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wells Fargo & Company reduced their price objective on Stryker from $456.00 to $418.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Canaccord Genuity Group reduced their price objective on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Deutsche Bank Aktiengesellschaft set a $315.00 price objective on Stryker in a research note on Friday, May 1st. Barclays reduced their price objective on Stryker from $469.00 to $394.00 and set an “overweight” rating on the stock in a research note on Monday, May 4th. Finally, JPMorgan Chase & Co. reduced their price objective on Stryker from $445.00 to $400.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Sixteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $395.48.

Insider Activity at Stryker

In related news, VP M Kathryn Fink sold 5,220 shares of the business’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the sale, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. The trade was a 28.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.60% of the company’s stock.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.